



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 03/30/2020 11:48
Last Report Issued 08/05/2015 07:53

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 1055B
Patient ID 1055B
Chain 15001958
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 15001958
Received 08/04/2015 06:25

Sample ID 15001958-001
Matrix Blood
Patient Name 1055B
Patient ID 1055B
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

| Analysis and Comments | Result | Units | Reporting Limit | Notes |
|-----------------------|--------|-------|-----------------|-------|
|-----------------------|--------|-------|-----------------|-------|

1055B Celecoxib, Blood

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

| | | | | |
|-----------------------|---------------|-------|----|--|
| Celecoxib | None Detected | ng/mL | 20 | |
| Synonym(s): Celebrex® | | | | |

Single oral doses of 100 and 200 mg in 4 subjects resulted in average peak plasma concentrations of 362 and 797 ng/mL, respectively, at times of 1.4 and 1.8 hours. Elimination half-lives in rapid and slow metabolizers averaged 14 and 52 hours, respectively.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.